A Korean study published recently suggests people with type 2 diabetes who are prescribed a particular class of drug might be ...

New research shows diabetes drugs may significantly reduce the risk of dementia, Alzheimer's, and Parkinson’s disease.

In patients older than 40 years, the type 2 diabetes drug class showed increased benefits over DPP-4 inhibitors at reducing ...

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, a class of diabetes drugs also known as gliflozins, could lower the risk ...

New data suggest that current recommendations overstate the proportion of patients who would receive significant kidney ...

Researchers have found that people who take a type of type 2 diabetes drugs SGLT2 inhibitors have a significantly lower risk ...

A specific class of diabetes drug appears to lower people's risk for dementia and Parkinson's disease, a new study shows.

According to a new study, certain diabetes medications may significantly reduce this risk. These drugs, called gliflozins or ...

A new study found a link between SGLT-2 inhibitors and a significantly lower risk of dementia in people with diabetes. Here's ...

A study reveals SGLT-2 inhibitors significantly reduce dementia risk in type 2 diabetes patients, with effects strengthening ...

A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease, according to a study ...

Scientists found a 22 percent lower risk of any dementia and Parkinson's among a group taking SGLT2 inhibitors for type 2 ...